IS4892A - Styrkt mótefnisblanda - Google Patents

Styrkt mótefnisblanda

Info

Publication number
IS4892A
IS4892A IS4892A IS4892A IS4892A IS 4892 A IS4892 A IS 4892A IS 4892 A IS4892 A IS 4892A IS 4892 A IS4892 A IS 4892A IS 4892 A IS4892 A IS 4892A
Authority
IS
Iceland
Prior art keywords
reinforced
antibody mixture
antibody
mixture
reinforced antibody
Prior art date
Application number
IS4892A
Other languages
English (en)
Inventor
Marcus Relton Julian
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4892(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS4892A publication Critical patent/IS4892A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS4892A 1996-05-24 1998-11-10 Styrkt mótefnisblanda IS4892A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9610992.1A GB9610992D0 (en) 1996-05-24 1996-05-24 Concentrated antibody preparation
PCT/EP1997/002595 WO1997045140A1 (en) 1996-05-24 1997-05-22 Concentrated antibody preparation

Publications (1)

Publication Number Publication Date
IS4892A true IS4892A (is) 1998-11-10

Family

ID=10794316

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4892A IS4892A (is) 1996-05-24 1998-11-10 Styrkt mótefnisblanda

Country Status (28)

Country Link
US (1) US6252055B1 (is)
EP (1) EP0907378B1 (is)
JP (1) JP3338060B2 (is)
KR (1) KR20000015935A (is)
CN (1) CN1219882A (is)
AP (1) AP9801392A0 (is)
AR (1) AR007249A1 (is)
AT (1) ATE318146T1 (is)
AU (1) AU731950B2 (is)
BR (1) BR9709267A (is)
CA (1) CA2254983A1 (is)
CO (1) CO4850562A1 (is)
CZ (1) CZ382498A3 (is)
DE (1) DE69735295T2 (is)
EA (1) EA001860B1 (is)
ES (1) ES2258277T3 (is)
GB (1) GB9610992D0 (is)
ID (1) ID16966A (is)
IL (1) IL126940A0 (is)
IS (1) IS4892A (is)
NO (1) NO985464L (is)
NZ (1) NZ332625A (is)
PE (1) PE69098A1 (is)
PL (1) PL330111A1 (is)
TR (1) TR199802423T2 (is)
WO (1) WO1997045140A1 (is)
YU (1) YU53098A (is)
ZA (1) ZA974486B (is)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU4314900A (en) * 1999-04-28 2000-11-17 Yamanouchi Pharmaceutical Co., Ltd. Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
AU2001278716A1 (en) * 2000-08-10 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Method of inhibiting antibody-containing solution from coagulating or becoming turbid
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US6365395B1 (en) 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
AU2006202688B2 (en) * 2001-05-31 2009-01-22 Genentech, Inc. Stable liquid formulations of antibodies
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
WO2003035004A2 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
AU2003212912A1 (en) 2002-02-04 2003-09-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
SI1475101T1 (sl) * 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2004210679A1 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
AU2012202845B2 (en) * 2003-02-10 2014-09-04 Biogen Ma Inc. Immunoglobulin formulation and method of preparation thereof
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CN1953768B (zh) * 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
US20080038253A1 (en) * 2004-03-04 2008-02-14 Cascalho Marilia I Methods For Altering T Cell Diversity
AU2005244842B2 (en) * 2004-05-12 2010-09-23 Baxter Healthcare S.A. Nucleic acid microspheres, production and delivery thereof
CN103393601A (zh) * 2004-05-12 2013-11-20 巴克斯特国际公司 含有蛋白并在高浓度蛋白下显示可注射性的微球体
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
AR053026A1 (es) 2005-03-08 2007-04-18 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
KR101363777B1 (ko) * 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
KR20150006085A (ko) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
JP5744513B2 (ja) * 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
EP2170949B1 (en) 2007-07-17 2012-12-26 F. Hoffmann - La Roche AG Variable tangential flow filtration
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009083225A2 (en) * 2007-12-28 2009-07-09 Biolnvent International Ab Formulation
WO2009129226A1 (en) 2008-04-15 2009-10-22 Talecris Biotherapeutics, Inc. Two-stage ultrafiltration/diafiltration
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
WO2010111378A1 (en) * 2009-03-24 2010-09-30 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
EP2542257B1 (en) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN103282042B (zh) 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
CN105854016A (zh) 2010-11-11 2016-08-17 艾伯维生物技术有限公司 改进的高浓度抗TNFα抗体液体制剂
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
AR087953A1 (es) 2011-08-26 2014-04-30 Baxter Int Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
EP2727643A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Cross-flow ultrafiltration device and method for concentration of pharmaceutical compositions
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
RU2675824C2 (ru) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
EA201692002A1 (ru) * 2014-04-07 2017-01-30 Сиэтл Дженетикс, Инк. Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
CN106999546A (zh) * 2014-05-01 2017-08-01 弗吉尼亚技术知识资产公司 角蛋白纳米材料及其制备方法
KR102497368B1 (ko) 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2020036903A1 (en) 2018-08-14 2020-02-20 Bristol-Myers Squibb Company Improved protein recovery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3272680D1 (en) * 1981-05-01 1986-09-25 Miles Lab Oral pharmaceutical composition containing immune globulin
JPH01268646A (ja) * 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
DE4211169C1 (is) * 1992-03-31 1993-06-03 Klaus Kretzschmar
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
SI2275119T1 (sl) * 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija

Also Published As

Publication number Publication date
PE69098A1 (es) 1998-12-02
BR9709267A (pt) 1999-08-10
EA001860B1 (ru) 2001-10-22
DE69735295D1 (de) 2006-04-27
EP0907378A1 (en) 1999-04-14
ATE318146T1 (de) 2006-03-15
EA199800946A1 (ru) 1999-06-24
ZA974486B (en) 1998-11-23
AU731950B2 (en) 2001-04-05
JPH11512753A (ja) 1999-11-02
US6252055B1 (en) 2001-06-26
DE69735295T2 (de) 2006-10-05
TR199802423T2 (xx) 1999-02-22
NZ332625A (en) 2000-04-28
IL126940A0 (en) 1999-09-22
EP0907378B1 (en) 2006-02-22
CO4850562A1 (es) 1999-10-26
CZ382498A3 (cs) 1999-05-12
AU2958997A (en) 1998-01-05
WO1997045140A1 (en) 1997-12-04
ID16966A (id) 1997-11-27
NO985464D0 (no) 1998-11-23
CN1219882A (zh) 1999-06-16
CA2254983A1 (en) 1997-12-04
KR20000015935A (ko) 2000-03-15
NO985464L (no) 1999-01-18
PL330111A1 (en) 1999-04-26
GB9610992D0 (en) 1996-07-31
AR007249A1 (es) 1999-10-27
ES2258277T3 (es) 2006-08-16
AP9801392A0 (en) 1998-12-31
JP3338060B2 (ja) 2002-10-28
YU53098A (sh) 2000-03-21

Similar Documents

Publication Publication Date Title
IS4892A (is) Styrkt mótefnisblanda
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
ATE199863T1 (de) Verstärktes bauelement
DE69403742D1 (de) Zementmischung
DE69405941D1 (de) Zementmischung
DE19782068T1 (de) Kraftstoffgemisch
NO981087D0 (no) Bitumenblanding
DE69618708D1 (de) Mischgerät
NO981626D0 (no) Sulfometylolerte ligninbaserte betongblandinger
DE69714864D1 (de) Verbesserte betonkonstruktion
FR2752391B3 (fr) Betonniere
DE69522730D1 (de) Armiertes Bauteil
ATA203796A (de) Zementbeschleuniger zementbeschleuniger
NO963318D0 (no) Sandströer
DE69713005D1 (de) Gegentaktmischer
FI98053B (fi) Sekoitus
ATA90296A (de) Stahlbetonbewehrung
KR970004178U (ko) 믹서기
DK33096A (da) Ringtrug-tvangsblander
DE69801254D1 (de) Immunoassay
KR960036243U (ko) 믹서기
BR9403663A (pt) Betoneira aperfeiçoada
BR9501126A (pt) Betoneira
FI955036A0 (fi) Vaermelagrande betongmassa
DK0889860T3 (da) Cementadditiver